Ginkgo Bioworks Holdings (DNA) Other Non-Current Liabilities (2019 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Other Non-Current Liabilities came in at $21.7 million in Q1 2026, up 40.84% YoY from $15.4 million in Q1 2025, and down 5.0% on a QoQ basis from $22.9 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Other Non-Current Liabilities (2019 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 8 years of Other Non-Current Liabilities data on file, last reported at $21.7 million in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 40.84% year-over-year to $21.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.7 million (up 40.84% YoY) and the FY2025 annual result came in at $22.9 million, up 38.01% from the prior year.
- Other Non-Current Liabilities declined to $21.7 million in Q1 2026, from $22.9 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $39.7 million in Q3 2022 to a low of $9.0 million in Q2 2022.
- A 5-year average of $20.3 million and a median of $17.9 million in 2025 frame the typical range for Other Non-Current Liabilities.
- The widest YoY moves for Other Non-Current Liabilities: up 194.01% in 2023, down 69.16% in 2023.
- Tracing DNA's Other Non-Current Liabilities over 5 years: stood at $31.2 million in 2022, then slipped by 21.67% to $24.4 million in 2023, then slumped by 32.16% to $16.6 million in 2024, then surged by 38.01% to $22.9 million in 2025, then dropped by 5.0% to $21.7 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $21.7 million (Q1 2026), $22.9 million (Q4 2025), and $17.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.37 Mn |
| Mar 31, 2026 | 21.73 Mn |
| Dec 31, 2025 | 22.88 Mn |
| Sep 30, 2025 | 17.16 Mn |
| Jun 30, 2025 | 17.94 Mn |
| Mar 31, 2025 | 15.43 Mn |
| Dec 31, 2024 | 16.58 Mn |
| Sep 30, 2024 | 17.67 Mn |
| Jun 30, 2024 | 20.90 Mn |
| Mar 31, 2024 | 24.88 Mn |
| Dec 31, 2023 | 24.43 Mn |
| Sep 30, 2023 | 12.26 Mn |
| Jun 30, 2023 | 14.15 Mn |
| Mar 31, 2023 | 29.34 Mn |
| Dec 31, 2022 | 31.19 Mn |
| Sep 30, 2022 | 39.74 Mn |
| Jun 30, 2022 | 9.01 Mn |
| Mar 31, 2022 | 9.98 Mn |
| Dec 31, 2021 | 58.56 Mn |
| Sep 30, 2021 | 14.07 Mn |